Minglei Chen

Dr. Minglei Chen

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MCMinglei Chen
Minglei Chen
KJKambere Amerigos Daddy J.C.
Kambere Amerigos Daddy J.C.
ZSZhigui Su
Zhigui Su
NGNida El Islem Guissi
Nida El Islem Guissi
YXYanyu Xiao
Yanyu Xiao
QPQineng Ping
Qineng Ping
Multifunctional nanomedicines with active targeting and stimuli-responsive drug release function utilizing pathophysiological features of the disease are regarded as an effective strategy for treatment of rheumatoid arthritis (RA). Under the inflammatory environment of RA, activated macrophages revealed increased expression of folate receptor and elevated intracellular reactive oxygen species (ROS) level. In this study, we successfully conjugated folate to polyethylene glycol 100 monostearate as film-forming material and further prepared methotrexate (MTX) and catalase (CAT) co-encapsulated liposomes, herein, shortened to FOL-MTX&CAT-L, that could actively target to activated macrophages. Thereafter, elevated intracellular hydrogen peroxide, the main source of ROS, diffused into liposomes and encapsulated CAT catalyzed the decomposition of hydrogen peroxide into oxygen and water. Continuous oxygen-generation inside liposomes would eventually disorganize its structure and release the encapsulated MTX. We characterized the in vitro drug release, cellular uptake and cytotoxicity studies as well as in vivo pharmacokinetics, biodistribution, therapeutic efficacy and safety studies of FOL-MTX&CAT-L. In vitro results revealed that FOL-MTX&CAT-L possessed sufficient ROS-sensitive drug release, displayed an improved cellular uptake through folate-mediated endocytosis and exhibited a higher cytotoxic effect on activated RAW264.7 cells. Moreover, in vivo results showed prolonged blood circulation time of PEGylated liposomes, enhanced accumulation of MTX in inflamed joints of collagen-induced arthritis (CIA) mice, reinforced therapeutic efficacy and minimal toxicity toward major organs. These results imply that FOL-MTX&CAT-L may be used as an effective nanomedicine system for RA treatment.

20 June 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
YYYuehai Yu
Yuehai Yu
SCShusen Chen
Shusen Chen
TLTujuan Li
Tujuan Li
SJShaohua Jin
Shaohua Jin
Guangyuan ZhangGuangyuan Zhang
Guangyuan Zhang
LLLi-jie Li
Li-jie Li
Dihydroxylammonium 5,5′-bistetrazole-1,1′-diolate (TKX-50) is a promising candidate to replace traditional explosives, HMX and RDX, used in insensitive munitions, which is currently being explored to achieve shock insensitive melt cast formulations.

23 February 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAmerigos Julien Claude Daddy Kambere
Amerigos Julien Claude Daddy Kambere
MCMinglei Chen
Minglei Chen
Faisal RazaFaisal Raza
Faisal Raza
YXYanyu Xiao
Yanyu Xiao
ZSZhigui Su
Zhigui Su
QPQineng Ping
Qineng Ping
Multidrug resistance (MDR) due to P-glycoprotein (P-gp) overexpression is a major obstacle to successful leukemia chemotherapy. The combination of anticancer chemotherapy with a chemosensitizer of P-gp inhibitor is promising to overcome MDR, generate synergistic effects, and maximize the treatment effect. Herein, we co-encapsulated a chemotherapeutic drug of mitoxantrone (MTO) and a P-gp inhibitor of β-elemene (βE) in solid lipid nanoparticles (MTO/βE-SLNs) for reversing MDR in leukemia. The MTO/βE-SLNs with about 120 nm particle size possessed good colloidal stability and sustained release behavior. For the cellular uptake study, doxorubicin (DOX) was used as a fluorescence probe to construct SLNs. The results revealed that MTO/βE-SLNs could be effectively internalized by both K562/DOX and K562 cells through the pathway of caveolate-mediated endocytosis. Under the optimized combination ratio of MTO and βE, the in vitro cytotoxicity study indicated that MTO/βE-SLNs showed a better antitumor efficacy in both K562/DOX and K562 cells than other MTO formulations. The enhanced cytotoxicity of MTO/βE-SLNs was due to the increased cellular uptake and blockage of intracellular ATP production and P-gp efflux by βE. More importantly, the in vivo studies revealed that MTO/βE-SLNs could significantly prolong the circulation time and increase plasma half-life of both MTO and βE, accumulate into tumor and exhibit a much higher anti-leukemia effect with MDR than other MTO formulations. These findings suggest MTO/βE-SLNs as a potential combined therapeutic strategy for overcoming MDR in leukemia.

1 July 2011 in Journal of Chinese Pharmaceutical Sciences
Verified
Journal Article
Open access
MCMinglei Chen
Minglei Chen
YFYun Fang
Yun Fang

1 April 2011
Verified
Journal Article
Closed access
MCMinglei Chen
Minglei Chen
JCJun Chen
Jun Chen
THTing Hou
Ting Hou
YFYun Fang
Yun Fang
WSWeiwei Sun
Weiwei Sun
BCBaocang Cai
Baocang Cai

1 January 2010
Verified
Journal Article
Closed access
JCJun Chen
Jun Chen
TZTing Zhang
Ting Zhang
BCBaochang Cai
Baochang Cai
MCMinglei Chen
Minglei Chen
YFYun Fang
Yun Fang